Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors
PUBT · 1d ago
Share
Listen to the news
- Shanghai Fosun Pharma unit Shanghai Fosun Pharmaceutical Industrial Development won China clearance for a new Luvometinib Tablets indication.
- Label expansion covers adult NF1 patients with symptomatic plexiform neurofibromas not suitable for complete surgical removal.
- Luvometinib is a self-developed MEK1/2 inhibitor; Fosun recorded about RMB 714 million in R&D spending as of July 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12318635), on September 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending